

Supplementary Material

Article Title: The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework

Authors: Rui Martins, MS; Aditi Kadakia, MS; G. Rhys Williams, PhD; Snezana Milanovic, MSc, MD; and Mark P. Connolly, MS, PhD

DOI Number: 10.4088/JCP.22m14746

1. [Appendix 1](#)

DISCLAIMER

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework

Appendix 1

Contents

1.	Modelling the clinical progression of schizophrenia	2
1.1.	Antipsychotic drugs efficacy and safety	2
1.1.1	Short-term antipsychotic use	2
1.1.2	Long-term antipsychotic use	3
1.2.	Search Strategy.....	3
1.3.	Eligibility criteria and study selection.....	4
1.4.	Mortality.....	5
	Cardiovascular risk covariates	5
2.	Modelling transitions between social states.....	7
2.1.	Incarceration.....	7
2.2.	Homelessness	9
3.	Likelihood of fiscal consequences	10
3.1.	Fiscal consequences for people living in the community.....	10
	Employment	10
	Caregiver consequences on employment	10
	Taxation	10
	Legal involvement.....	11
	Disability benefits	11
	Victimization.....	11
	Healthcare Insurance.....	11
3.2.	Fiscal consequences in incarcerated and homeless individuals.....	11
	Remission versus relapse	13
4.	Fiscal costs and economic consequences.....	13
5.	Additional results.....	15
6.	References	16

1. Modelling the clinical progression of schizophrenia

The model compares a cohort unaffected by schizophrenia (general US population) with a cohort with schizophrenia from the age of 23 years, over an 80-year time horizon. The disease progression model simulates individuals' response to six sequences of antipsychotic treatments (Table 1). The average of all sequences of antipsychotics (AP) is finally used to predict the proportion of people with schizophrenia in remission or relapse.

Table 1 – Antipsychotic sequences used in the model

Seq.	First line AP	Second Line AP	Third line AP	Long-term treatment ^a
1	Quetiapine	Aripiprazole		(40.0%) No treatment
2	Aripiprazole			(46.8%) Average oral APs
3	Risperidone	Quetiapine	Average oral AP	(10.1%) Average LAIs
4	Olanzapine			(3.1%) Clozapine
5	Lurasidone			

Acronyms: AP, antipsychotic, LAI, Long-acting injectable antipsychotics

The AP agent with the highest market share utilization, not used as first-line treatment, was selected as second-line agent. The market shares used to establish treatment sequences and calculate the average efficacy and safety for oral APs were: 34.0% quetiapine, 18.0% aripiprazole, 16.0% risperidone, 12.0% olanzapine and 4.0% lurasidone.¹ The market shares used to calculate the average efficacy and safety for LAIs were: 66.0% paliperidone LAI, 29.3% risperidone LAI, 3.3% aripiprazole LAI, and 1.5% olanzapine LAI.²

^a On the long-term 40.0% of people were assumed not to receive any treatment for schizophrenia. ³ The distribution long-term AP treatments was informed by Medicaid data. ² Bareis and colleagues reported that 85.5% of patients would receive an AP (any), 14.4% LAIs, and 4.4% clozapine. These proportions were rearranged to be expressed as a proportion of the 60% receiving AP treatment (i.e., $60.0\% \times [85.5\% - 14.4\% - 4.4\%] / 85.5\% = 46.8\%$).

1.1. Antipsychotic drugs efficacy and safety

1.1.1 Short-term antipsychotic use

The probabilities of discontinuing during the trial period were calculated from the rates of all cause discontinuation reported by published randomized controlled trials (RCTs) assessing the efficacy of oral APs. The likelihood of stable disease (remission) was calculated as 1 minus the probability of all cause discontinuation. The mean weight gain related to each AP was also obtained from published RCTs. The probabilities of unstable disease and mean weight gain used in the model are shown in Table 2 (trial period).

Table 2 – Probability of unstable disease and mean weight gain during the trial period, adjusted for 6-week cycle length

Antipsychotic agent	Probability of discontinuation ^a	Sources	Mean weight gain (Kg)	Sources
Quetiapine	0.417	4-16	1.644	4-11 15 17
Aripiprazole	0.328	7 8 16 18-30	0.692	8 18-20 23 25-27 29
Risperidone	0.304	8 13 15 16 19 25 27 29 31-45	1.930	8 15 19 25 27 29 30 32 40-42 46 47
Olanzapine	0.266	8 13 21 22 24 32 34 48-66	2.346	8 17 32 34 49 51 53-67
Lurasidone	0.337	11 36 39 59 68-73	0.491	11 39 59 68-73

^a Defined as treatment inefficacy, occurrence of intolerable adverse effects (AE), or treatment discontinuation due to patient's decision at the end of the trial period. The probability of relapse was defined as one minus the probability of all cause discontinuation. It is likely that several sequences are used in clinical practice so efficacy and safety estimates for an average AP drug were calculated using arithmetic means, weighted according to the market shares for quetiapine, aripiprazole, risperidone, olanzapine, and lurasidone.¹

The probability of unstable disease (relapse) and mean weight gain in people receiving maintenance therapy was sourced from an US cost-effectiveness analysis evaluating the use of atypical AP in the treatment of schizophrenia.⁷⁴ The likelihood of hospitalization was used as a proxy for the probability of unstable disease. The inputs utilized in the model are shown in Table 3.

Table 3 – Probability of unstable disease and mean weight gain during the maintenance period, adjusted for 6-week cycle length

Antipsychotic agent	Probability of relapse	Mean weight gain (Kg)
---------------------	------------------------	-----------------------

Quetiapine	0.123	0.315
Aripiprazole	0.118	0.238
Risperidone	0.097	0.252
Olanzapine	0.075	1.259
Lurasidone	0.084	0.081
Clozapine	0.053	0.315

Source: O'Day 2013⁷⁴

The literature search strategy used to identify RCT evidence of the efficacy and safety of APs and the PICOS strategy detailing the inclusion criteria are presented in subsequent sections.

1.1.2 Long-term antipsychotic use

Individuals presenting with active disease, despite third-line AP therapy, entered the long-term phase of the model. The distribution of individuals across long-term treatments is depicted in Table 1. People receiving AP treatment were assumed to achieve stable disease, being at risk of relapse. On the long-term, the efficacy and safety of oral APs were calculated as the average of individual APs effects during maintenance phase⁷⁴ (Table 3), weighted according to their US market shares.¹ Evidence informing the efficacy and safety of clonidine was also sourced from the cost-effectiveness study by O'Day et al.⁷⁴

Evidence of the efficacy and safety of LAIs was sourced from a network meta-analysis (NMA) of APs.⁷⁵ The efficacy of LAIs was reported as pooled odds ratios (OR) compared to placebo. It was assumed that placebo would be a proxy for no treatment and that 74.1%⁷⁶ of all untreated individuals would present with active disease. Odds ratios were rearranged to relative risks (RR) using Equation 1⁷⁷ before being applied to the baseline probability of being in active disease.

$$RR = \frac{OR}{(1 - p_0 + (p_0 * OR))} \quad \text{Equation 1}$$

Where p_0 is the baseline probability of the event.

Evidence for 4 LAIs was selected for use in the model (paliperidone LAI, risperidone LAI, aripiprazole LAI, and olanzapine LAI) matching the availability of US market shares for LAIs identified in the literature.⁷⁸ The odds ratios of unstable disease and mean weight gain associated with LAIs use is shown in Table 4.

Table 4 – Odds ratios of unstable disease and mean weight gain associated to long-term use of LAIs

Antipsychotic agent	OR, relapse vs placebo	Mean weight gain (Kg) ^a
Aripiprazole LAI	0.690	-0.032
Olanzapine LAI	0.160	0.291
Paliperidone LAI	0.300	0.171
Risperidone LAI	0.100	0.279

Source: Schneider-Thoma 2022⁷⁵

Acronyms: LAI, long-acting injectable antipsychotic; OR, odds ratios.

^a Cycle-adjusted.

1.2. Search Strategy

The OVID platform was used to conduct searches in the following literature databases: EMBASE, MEDLINE, including MEDLINE (R) In process, MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE Daily, Medline and Versions, Cochrane Central Register of Controlled Trials (CENTRAL) and PSYcINFO. Searches were conducted from inception to September 4th, 2020. The search strategy was based on the combination of free text words, indexing terms (e.g. Excerpta Medica database [EMBASE] subject heading [EMTREE] or Medical Subject Headings [MESH] terms) and their relationship using Boolean terms (e.g. 'and', 'or', 'not'). Full search strategies are specified in Table 5.

Table 5 – Literature search strategy

#	Searches
1	((exp *schizophrenia spectrum disorder/ or schizopreni*.ti. or exp *Schizophrenia Spectrum/) and Other Psychotic Disorders/) or exp *Schizophrenia/
2	randomi*.mp. or exp Randomized Controlled Trial/
3	1 and 2
4	3 not ('case report' or 'case reports' or editorial or comment).ti,pt,xs,sh.
5	limit 4 to English language
6	De-duplicate

In addition, the following relevant conference websites were searched to identify relevant abstracts accepted at the most recent meeting only (abstracts from prior meetings were indexed in Ovid):

1. International College of Neuropsychopharmacology
2. American Psychiatric Association
3. U.S. Psychiatric & Mental Health
4. American Society of Clinical Psychopharmacology
5. American College of Neuropsychopharmacology
6. European College of Neuropsychopharmacology
7. European Congress of Psychiatry
8. European Psychiatric Association
9. Neuroscience Education Institute
10. Schizophrenia International Research Society (SIRS)

Bibliographies of up to three recent reviews on the efficacy and safety of atypical antipsychotics and LAIs in schizophrenic patients were cross-checked to identify additional studies.

Clinicaltrials.gov was consulted to search for any information that could be missing from the primary publication. No search was performed on clinicaltrials.gov for trial identification.

1.3. Eligibility criteria and study selection

The publications identified by the literature search were sifted by 2 researchers based on titles and abstracts according to pre-established criteria (Table 1). Full papers were then inspected and considered for inclusion. Data extraction was conducted by a single reviewer.

Table 6 – PICOS strategy

PICOS	Inclusion Criteria	Exclusion Criteria
Population	Adults (≥ 18 years) and adolescents with schizophrenia	<ul style="list-style-type: none"> • Studies with patients who do not have schizophrenia • Pregnant
Intervention	SGAs ^a approved in the US or Europe and new experimental treatments as monotherapy or their combination <ul style="list-style-type: none"> • Oral treatment • Long-acting injectables 	<ul style="list-style-type: none"> • Interventions that are not SGAs • Studies with no pharmacological therapy
Comparison	Any of the above listed interventions and placebo	Not applicable
Outcomes	Baseline, change from baseline Primary timepoints include 6 +/- 2 weeks and potential to include 12 +/- 3 weeks Primary outcome: <u>Efficacy</u> <ul style="list-style-type: none"> • Positive and Negative Syndrome Scale (PANSS) Secondary Outcome: <u>Efficacy</u> <ul style="list-style-type: none"> • Brief negative symptom scale • The Montgomery-Åsberg Depression Rating Scale (MADRS) 	Studies with other outcomes only

	<ul style="list-style-type: none"> • Clinical Global Impression – Severity scale (CGI-S) • Response 	
	<u>Metabolic</u> <ul style="list-style-type: none"> • Weight gain • ≥7% weight gain 	
	Discontinuation <ul style="list-style-type: none"> • All-cause discontinuation • Discontinuation due to lack of efficacy • Discontinuation due to adverse events 	
Study Design	<ul style="list-style-type: none"> • Randomized controlled trials (RCTs) 	<ul style="list-style-type: none"> • Other study designs
Filters	<ul style="list-style-type: none"> • English language • Search: no date limit 	<ul style="list-style-type: none"> • Historically assessed experimental therapies: studies published before 2015 for experimental SGAs that are not approved in the US or Europe • Publication types: editorials, letters, notes, commentaries, reviews

Acronyms: RCTs, randomized controlled trials; SGAs, second-generation antipsychotics; US, United States

^a SGAs approved in the United States and Europe only at the approved doses will be included. For newer experimental treatments not yet approved, all doses will be included.

Antipsychotic-specific outcomes for the probability of unstable disease and weight gain were calculated using arithmetic averages weighted by study sample size. The resulting estimates were used as absolute probabilities in the model. This simplified approach was preferred (to indirect treatment comparison) because the main goal of the evidence review was to calculate the efficacy and safety of an AP therapy (representative of AP with largest market share), rather than comparing one AP or sequence of APs to another.

1.4. Mortality

Mortality was modelled using a lifetable method based on annual mortality rates published by Arias and Xu.⁷⁹ The annual mortality rates due to suicide or due to cardiovascular disease in the general population were disaggregated from overall mortality using age and gender specific US prevalence figures for suicide and CVD-related mortality.⁸⁰ The resulting risk of suicide was multiplied by published standardized mortality ratios (SMR) in males (SMR 3.39 standard error [SE] 0.03) and females (SMR 8.16, SE 0.04) to derive the increased risk of suicide in the schizophrenia population.⁸¹

The baseline risk of a cardiovascular event was estimated using the Framingham risk equations featuring body mass index (BMI) predictors.^{82,83} The likelihood of death after a cardiovascular event was sourced from a US publication reporting the case fatality rate in individuals having cardiovascular events.⁸⁴ The input used in the model (9.5%) was calculated as the weighted average of the case fatality rate amongst people having a myocardial infarction, cardiac arrest, and ischemic or hemorrhagic stroke.

Cardiovascular risk covariates

Gender, age, BMI, systolic blood pressure (SBP) in treated or untreated, diabetes and smoking status covariates were required to inform the Framingham equations. Age and sex were obtained from the progressing model cohort. The remaining inputs were sourced from the literature and are shown in Table 7.

BMI was calculated as the weight in kilos divided by the squared height in centimeters. The height and weight for males and females at the start of the model (30 years) was sourced from average age-specific values from the general US population.⁸⁵ The same values were used for the population with schizophrenia. Weight gain due to AP use was modelled in the schizophrenia cohort using efficacy and safety data from trial and maintenance periods APs (Table 2 and Table 3). To avoid indefinite weight increase in people receiving AP therapy, a cutoff point of 7% increase from baseline weight was implemented in the model. It was assumed that people would not return to baseline body weight.

The distribution and SBP values for individuals with normal blood pressure or with hypertension on/off treatment were sourced from US health statistics.⁸⁶ The age specific prevalence of diabetes in the group unaffected by schizophrenia was informed by general US population data.⁸⁷ The likelihood of diabetes in the schizophrenia population was estimated by adjusting the US population prevalence values using an odds ratio (OR 1.83, 95% CI 1.29 to 2.60) sourced from an US study comparing 326 individuals with schizophrenia or schizoaffective disorder to 1,899 controls.⁸⁸ The prevalence of smoking in the general population used US age and gender specific data.⁸⁹ The excess likelihood of smoking in people with schizophrenia was informed by a meta-analysis studying the association between schizophrenia and tobacco use (OR 5.30, 95% CI 4.90 to 5.70).⁹⁰ Before being applied to the general population values, the ORs were converted to relative risks (RR) using Equation 1.⁷⁷

Table 7 – Mean inputs informing cardiovascular risk factors in the model

Description	Males	Females	SE	Source
Risk of death from a cardiovascular event	9.5% ^a		20% of mean	⁸⁴
Body mass Index				
Weight (Kg)	94.40	79.30	[1.21], [0.99]	⁸⁵
Height (cm)	176.30	162.70	[0.40], [0.37]	
Diabetes				
Prevalence of diabetes in US general population	17.9%	16.2%	[0.8%], [0.7%]	⁸⁷
Prevalence of diabetes by age				
18 to 44 years	4.9%		0.8%	
45 to 64 years	14.8%		0.7%	
65+ years	14.3%		0.5%	⁸⁸
OR diabetes (schizophrenia vs US population)	1.83		0.18	
Hypertension				
Prevalence of hypertension in US population	33.1%	35.2%	[0.5%], [0.5%]	⁸⁶
Treated hypertension	63.4%	71.3%	[0.8%], [0.8%]	
Untreated hypertension	36.6%	28.7%	[0.8%], [0.8%]	
SBP, no hypertension (mmHg)				
18 to 39 years	117	109	[0.4], [0.6]	
40 to 59 years	119	115	[0.3], [0.4]	
60+ years	121	122	[0.3], [0.2]	
SBP, hypertensive, treated (mmHg)				
18 to 39 years	127	123	[0.7], [0.6]	
40 to 59 years	129	129	[0.7], [0.9]	
60+ years	135	141	[1.2], [1.5]	
SBP, hypertensive, untreated (mmHg)				
18 to 39 years	140	140	[0.7], [0.8]	
40 to 59 years	145	149	[0.9], [0.8]	
60+ years	154	159	[0.7], [1.8]	
Smoking				
Prevalence of smoking by age				⁸⁹
18 to 24 years	18.2%		1.0%	
25 to 44 years	25.3%		0.6%	
45 to 64 years	23.0%		0.6%	
65+ years	11.4%		0.4%	
Prevalence of smoking by gender	62.5%	37.5%	[0.5%], [0.4%]	⁹⁰
OR smoking (schizophrenia vs US population)	5.30 ^b		0.17	

Acronyms: OR, odds ratio; SE, standard error; SBP, systolic blood pressure; US, United States.

^a Weighted average of the case fatality rates for myocardial infarction, cardiac arrest, and ischemic or hemorrhagic stroke.

^b Applied to the prevalence of smoking in the general population to derive the likelihood of smoking in people with schizophrenia.

2. Modelling transitions between social states

2.1. Incarceration

Age and gender adjusted lifetime probabilities of incarceration in prisons for the adult US general population were sourced from a publication by the Bureau of Justice Statistics.⁹¹ These probabilities were annualized using Equation 2.

$$p = 1 - \exp\left(\frac{\ln(1 - p_i)}{t_i} * t\right) \quad \text{Equation 2}$$

where p_i is the age and gender specific index probability, t_i the index time calculated as the maximum for the age category minus the minimum age of incarceration (18 years), and t is the cycle length. The maximum age at which individuals would be incarcerated was implemented as 70 years as based on a publication by US Department of Justice.⁹² The number of incarcerations in jails were estimated by multiplying these probabilities by a ratio of jail to prison incarceration. The ratio (0.540) was obtained by dividing the proportion of individuals sentenced to jails (33.5% [738,400/2,203,600]) by the proportion of individuals sentenced to prisons (66.5% [1,465,200/2,203,600]) in 2019.⁹³

The probability of incarceration in people with schizophrenia was obtained by multiplying the probability of incarceration in the general population by the relative risk (RR) of incarceration in people with schizophrenia. Different RR were calculated to translate the likelihood of incarceration in prisons (3.99) or jails (5.93). These RRs were calculated by dividing the prevalence of incarceration in the US general adult population (0.9% [2,123,100/255,200,373]) by the prevalence of schizophrenia in US prisons. The prevalence of schizophrenia in US prisons was calculated by averaging the values reported by a systematic review of US studies.⁹⁴ Due to heterogeneity in the values reported by Prins and colleagues, we ran a scenario using calculated values for the prevalence of schizophrenia in US prisons (8.7% [125,437/1,441,800])⁹⁵ or US jails (11.70% [84,263/720,200]).⁹⁵ The prevalence estimates reported by Bronson and Berzofsky⁹⁵ considered inmates with schizophrenia and other psychotic disorders in prison and jail. These estimates were adjusted using the proportion of people with schizophrenia amongst the population with schizophrenia and other psychotic disorders (46.1%).⁹⁶

The time dependence associated to varying durations of incarceration reported in the literature were accounted for by implementing a series of tunnel states (20 for prisons and 6 for jails).^{97,98} After being released, individuals entered a sequence of 5 ex-convict tunnel states to account for the increased likelihood of reincarceration in this population.⁹⁹ When ex-convicts returned to the community state, the model was no longer able to determine if they were ever incarcerated.

The higher probability of incarceration in homeless people was implemented by multiplying the probability of incarceration for community dwelling individuals by the relative risk of incarceration in the homeless (9.03). This ratio was calculated by dividing the proportion of individuals in jail who were homeless (15.3%) by the annual rate of homelessness in the general population (1.7%), both sourced from a survey of 6,953 US jail inmates.¹⁰⁰

Incarceration rate ratios for individuals in remission or relapse versus the general schizophrenia population were calculated by dividing the cumulative incidence of arrests in people with remission or relapse by the cumulative incidence of arrests in the entire sample of people with schizophrenia, as reported in the US longitudinal study conducted by Haynes and colleagues.¹⁰¹ Arrest does not mandate incarceration, nonetheless the likelihood of arrest was perceived as a reasonable proxy for incarceration, as it implies a level of offense punishable by law. All inputs related to the likelihood and duration of (re)incarceration are available in Table 8.

Table 8 - Inputs informing the likelihood and duration of (re)incarceration

Description	Input	SE	Source
Total US population 2021	258,327,312	Not varied	102
Likelihood and duration of incarceration			
Lifetime probability of incarceration in the US population ^a			
Age groups	Males	Females	91
65+	3.1%	0.2%	
55 to 64	4.0%	0.3%	
45 to 54	5.3%	0.6%	0.001%
35 to 44	6.5%	0.9%	
25 to 34	6.0%	0.7%	
18 to 24	2.7%	0.2%	
Total individuals incarcerated in the US	2,123,100 (100%)	Not varied	93
Prison	1,465,200 (66.5%)	Not varied	
Jail	738,400 (33.5%)	Not varied	
% US population incarcerated	0.9%	Not varied	Calculated
Duration of incarceration in prison ^b			
21 years	100.0%		98
20 years	99.0%		
10 years	95.8%		
5 years	87.7%	Not varied	
3 years	77.1%		
2 years	66.1%		
1 year	41.9%		
Duration of incarceration in jail ^b			
6 years	100.0%		97
5 years	93.6%		
3 years	88.6%	Not varied	
2 years	85.2%		
1 year	76.5%		
Recidivism in the general US population			
Cumulative percentage of rearrests in the general US population			
5 years	70.8%	0.2%	99
4 years	67.0%	0.2%	
3 years	61.5%	0.2%	
2 years	52.9%	0.2%	
1 years	36.8%	0.2%	
Cumulative percentage of rearrests leading to conviction in the general US population			
5 years	54.4%	0.2%	99
4 years	50.6%	0.2%	
3 years	45.0%	0.2%	
2 years	36.5%	0.2%	
1 years	22.9%	0.2%	
Incarceration in people with schizophrenia			
Prevalence of schizophrenia in US prisons			
Prevalence of schizophrenia and other psychotic disorders in prison	3.44%	1.04%	94
Prevalence of schizophrenia and other psychotic disorders in jail	8.7% ^c	0.02%	95
RR of going to prison (schizophrenia vs US population)	11.7% ^c	0.04%	
RR of going to jail (schizophrenia vs US population)	3.99	Not varied	Calculated
	5.93	Not varied	Calculated
Incarceration in the homeless population			
Proportion of individuals in jail who were homeless	15.3%		100
Annual rate of homelessness in general population	1.7%	20% of mean	
RR incarceration in homeless vs general US population	9.03		Calculated

Acronyms: RR, relative risk; SE; standard error; US, United States

^a The lifetime probabilities of incarceration were annualized based on the published probabilities using Equation 2. The period for the rate was calculated by subtracting the minimum age of incarceration (18 years) by the upper age in the age category i.e., 35 to 44 years category, 45-18=27 years; 25 to 34 years category, 35-18=17 years.

^b Considered to be the same in the general population and in people with schizophrenia.

^c Used in scenario analysis.

2.2. Homelessness

The inputs utilized to inform transitions to the homeless social state and homelessness recurrence are shown in Table 9. The age adjusted annual probabilities of homelessness were calculated by multiplying the prevalence of homelessness in the general population by the age distribution of sheltered individuals in one year (October 2009 to September 2010).¹⁰³ The prevalence of homelessness in the general population (0.7%) was calculated by dividing the number of individuals experiencing homelessness in one year in 2010 (1,593,150)¹⁰³ by the total US population in 2010 (234,564,071).¹⁰⁴

The probability of homelessness in people with schizophrenia was implemented by multiplying the probability of becoming homeless in the general US population by the relative risk of homelessness in the schizophrenia populations. The relative risk of homelessness in the population with schizophrenia (15.55) was calculated by dividing the prevalence of schizophrenia in the homeless population (10.6%)¹⁰⁵ by the prevalence of homelessness in the general population (0.7%).

Table 9 – Inputs informing the likelihood of (repeated) homelessness

Description	Input	SE	Source
Homelessness in the general US population			
Total US population in 2010	234,564,071	Not varied	¹⁰⁴
Individuals experiencing homelessness in 1 year (2010)	1,593,150	Not varied	¹⁰³
% Homelessness in US population (1 year)	0.7%	Not varied	Calculated
Age distribution for homeless population (one single night)			
<18 years	21.8%	0.05%	¹⁰³
18 to 30 years	23.5%	0.05%	
31 to 50 years	37.0%	0.06%	
51 to 61 years	14.9%	0.05%	
62+ years	2.8%	0.02%	
Probability of being sheltered			
% Sheltered	61.1%	0.1%	¹⁰⁶
% Unsheltered	38.9%	0.1%	
Homelessness in people with schizophrenia			
Prevalence of schizophrenia in homeless population	10.6%	2.5%	¹⁰⁵
RR of homelessness vs general population	15.55		Calculated
RR of homelessness after previous shelter use	8.33	0.152	¹⁰⁷
RR of homelessness in ex-convicts with mental illness	2.47	0.18	

Acronyms: RR, relative risk; SE, standard error; US, United States.

The rate ratios of the likelihood of homelessness for those in remission or relapse were calculated using Adelphi real-world data¹⁰⁸ (Table 11). These ratios were multiplied by the cycle probability of homelessness in the general schizophrenia population, so that the estimates were adjusted to individuals' remission or relapse status.

There is evidence suggesting that ex-convicts have a higher risk of homelessness, compared to the general population. In the general population, the probability of homelessness after release from incarceration used annualized age specific values published by Metraux.¹⁰⁹ Remster and colleagues¹⁰⁷ suggested that ex-convicts with mental illness were approximately 2.47 times more likely to become homeless, compared to the ex-convicts without mental illness. Therefore, this estimate was multiplied by the general population probabilities to obtain the probabilities in the cohort with schizophrenia.

The probability of returning to homelessness was informed by an US publication suggesting that individuals who had been sheltered before had 8.3 higher risk of experiencing homelessness again versus the general population.¹⁰⁷ This estimate was multiplied by the probability of homelessness in the general population or in the schizophrenia cohort to obtain the annual probability in ex-homeless individuals.

3. Likelihood of fiscal consequences

Costs were linked to fiscal consequences to generate total costs for people with and without schizophrenia. Due to the lack of schizophrenia-specific data we assumed that the annual healthcare costs per capita for homeless people with or without schizophrenia would be the same.

3.1. Fiscal consequences for people living in the community

Employment

The level of employment in the general population was implemented using age and gender-specific prevalence figures from the US Bureau of Labor Statistics¹¹⁰ Following these distributions most individuals stop working around the age of retirement (65 to 67 years) although some do stay employed. Because there is no age at which individuals must stop working, we assumed 70 as the age after which individuals would no longer be employed.

An US publication estimated the likelihood of employment in people with schizophrenia (OR 0.24, 95% CI 0.16 to 0.37) compared to individuals unaffected by schizophrenia, using data from the National Health Interview Survey.¹¹¹ This value was applied to the rates of employment in the general US population to estimate employment in the schizophrenia cohort. The likelihood of employment in people with remission or relapse was adjusted using rate ratios estimated from an analysis of US Adelphi data¹⁰⁸ (Table 11).

Caregiver consequences on employment

Informal caregivers were modelled uniquely to estimate the impact of weekly hours of informal care on labor participation. We assumed that caregivers would be mostly females (59.2%) have a mean age of 48.3 years.¹¹² Annual mortality used general US lifetables.⁷⁹ Informal caregivers' employment was conditional to age-specific probabilities of employment¹¹⁰ In those predicted to work, the proportion of a full-time equivalent (FTE) in males and females was calculated using the equations below publication sourced from a Canadian publication.¹¹³

$$Proportion_{FTE\ Males} = \exp(-0.045Primary_{CG} - 0.032Care_{10} - 0.089Care_{15} - 0.156Care_{20}) \quad \text{Equation 3}$$

$$Proportion_{FTE\ Females} = \exp(-0.037Primary_{CG} + 0.023Care_{10} - 0.022Care_{15} - 0.018Care_{20}) \quad \text{Equation 4}$$

Where $Primary_{CG}$ took the value of 1 for primary caregivers (assumed all were primary caregivers), and $Care_{10}$, $Care_{15}$ and $Care_{20}$ took the value of 1 if informal care was provided for more than 10, 15 or 20 hours weekly, respectively, and took the value of 0 otherwise.

The proportion of individuals in the general US population having informal caregivers (15.6%) and the weekly average provision of informal care (10.0 hours) were informed by national US data.¹¹⁴ Weekly hours of care in people with schizophrenia in remission and relapse was sourced from an analysis of US Adelphi data.¹⁰⁸

Taxation

Direct taxes were calculated by multiplying gross income from employment (in people with schizophrenia, caregivers, and general population equivalents) by the US tax wedge (28.4%).¹¹⁵ The tax wedge represents the amount of taxes and social security contributions related to a single worker. Taxes are paid by the employee and social security contributions are paid by the employee and employer. Indirect taxes were calculated by multiplying the consumption tax rate (10.1%)¹¹⁶ by the disposable income of all individuals in the model. The rate of disposable income was calculated by dividing the average annual disposable income values by the average annual earnings from employment.¹¹⁷ The resulting figure was used to estimate the share of individual's earnings or fiscal benefits spent on consumption and paid consumption taxes.

Legal involvement

Only a proportion of arrests result in individuals being incarcerated (66.0%).¹¹⁸ We therefore implemented the number of people being arrested as 34.0% more than the individuals predicted by the model to be incarcerated.

Disability benefits

The proportion of people receiving Social Security Disability Insurance (SSDI), Supplemental Security Income (SSI) or both was informed by the Social Security administration (SSA) 2019 report.¹¹⁹ We estimated that 6.6% of the entire schizophrenia population is a recipient of disability benefits, compared to 3.7% of the general US population. The age distribution of these recipients was also informed by SSA data.¹¹⁹ In the absence of specific data we have assumed that people able to maintain a job would not be a recipient of SSA benefits. This is a simplification of reality as work incentives by the SSA enable employed individuals to still receive monthly financial support as well as Medicaid and Medicare services during a trial work period.¹²⁰

Victimization

The likelihood of being victim of a crime in the general US population was modelled using data published by the US Department of Justice.¹²¹ The relative risk of violent victimization in people with schizophrenia was obtained by dividing the annualized probability of violent victimization in people with schizophrenia¹²² by the probability of violent victimization in the general population.¹²¹

Healthcare Insurance

Healthcare costs incurred by the US government were considered part of the fiscal expenses. In the general US population the proportion of individuals using publicly funded healthcare insurance was informed by US Census Bureau data.¹²³ In the schizophrenia population these parameters were sourced from an analysis of Medical Expenditures Panel Survey¹²⁴ suggesting most individuals with schizophrenia would use publicly funded healthcare insurances.¹²⁵

3.2. Fiscal consequences in incarcerated and homeless individuals

All individuals who were in prisons or jails incurred the costs of incarceration and were also assigned different healthcare costs than same age individuals living in the community. A similar approach was used for individuals who became homeless. An assumption was made that people who were homeless or incarcerated would use 100% publicly funded healthcare insurance. Ex-convicts and ex-homeless people were assumed to have the same rates of public healthcare financing than the remaining individuals living in the community.

Table 10 – Inputs used to model the likelihood of fiscal consequences

Description	Input		SE	Source
Employment general US population				
Age category	Males	Females		
75+ years	11.1%	11.1%	[0.01%], [0.01%]	
70 to 74 years	21.1%	21.1%	[0.02%], [0.02%]	
65 to 69 years	35.9%	35.9%	[0.02%], [0.02%]	
60 to 64 years	59.0%	59.0%	[0.02%], [0.02%]	
55 to 59 years	73.3%	73.3%	[0.01%], [0.01%]	
50 to 54 years	80.1%	80.1%	[0.01%], [0.01%]	
45 to 49 years	83.4%	83.4%	[0.01%], [0.01%]	110
40 to 44 years	83.1%	83.1%	[0.01%], [0.01%]	
35 to 39 years	85.1%	85.1%	[0.01%], [0.01%]	
30 to 34 years	82.4%	82.4%	[0.01%], [0.01%]	
25 to 29 years	77.1%	77.1%	[0.01%], [0.01%]	
20 to 24 years	61.3%	61.3%	[0.02%], [0.02%]	
18 to 19 years	38.5%	38.5%	[0.02%], [0.02%]	
Employment in people with schizophrenia				
OR employment (schizophrenia vs US population)	0.24		0.21	111
Disability - US population not affected by schizophrenia				

All disabled beneficiaries (2019)	9,562,282	Not varied	119
All US population (2019)	328,239,523	Not varied	126
Disabled beneficiaries excluding schizophrenia population as proportion of total US population (2019)	2.9% ^a	Not varied	Calculated
Distribution of disabled beneficiaries (all beneficiaries)			
60+	39.0%	0.02%	
50-59	38.2%	0.02%	
40-49	14.6%	0.01%	119
30-39	6.7%	0.01%	
Under 30	1.5%	0.00%	
Disabled beneficiaries receiving Social Security benefits			
SSDI only	62.2%	0.01%	
SSI only	28.0%	0.01%	119
Both SSDI and SSI	9.8%	0.01%	
Disability - Schizophrenia population			
All beneficiaries with schizophrenia or other psychotic disorders	463,142	Not varied	119
Beneficiaries with schizophrenia	202,814 ^b	Not varied	Calculated
Total population with schizophrenia (>18 years, 2019)	3,036,884	Not varied	126
Disabled beneficiaries with schizophrenia as proportion of total schizophrenia population	6.7% ^c		Calculated
Distribution of disabled beneficiaries (people with schizophrenia and other psychotic disorders)			
60+	23.6%	0.07%	
50-59	33.6%	0.08%	
40-49	22.7%	0.07%	119
30-39	15.7%	0.06%	
Under 30	4.3%	0.03%	
Disable beneficiaries receiving SSA benefits			
SSDI only	43.9%	0.06%	
SSI only	40.7%	0.06%	119
Both SSDI and SSI	15.4%	0.04%	
Probability of victimization in the general US population			
Probability of violent victimization 2019 (all types)	2.1%	0.001%	121
Distribution of violent victimization by age (excluding simple assault)			
65+ years	0.4%	0.001%	
50 to 64 years	1.0%	0.001%	
35 to 49 years	1.1%	0.001%	121
25 to 34 years	1.5%	0.002%	
18 to 24 years	1.7%	0.002%	
12 to 17 years	1.6%	0.003%	
Victimization in the schizophrenia population			
People with schizophrenia who were victims of a violent crime over 3 years	34.3%	3.6%	122
Annualized probability of violent victimization in people with schizophrenia	13.1%	Not varied	Calculated
RR violent victimization (schizophrenia vs general population)	6.22 ^d	Not varied	Calculated
Criminal justice			
Conviction rates for felony defendants	66.0%	20% of mean	118
Public healthcare financing in the general US population			
General US population			
65+ years	93.6%	0.003%	
55-64 years	20.5%	0.006%	
45-54 years	15.4%	0.006%	
35-44 years	16.3%	0.006%	102
26-34 years	18.2%	0.006%	
19-25 years	18.2%	0.007%	
06-18 years	35.1%	0.005%	
People with schizophrenia			
65+ years	96.7%	0.10%	
40-64 years	75.1%	0.08%	125
18-39 years	73.1%	0.11%	

Acronyms: OR, odds ratio; RR, relative risk; SE, standard error; SSDI, Social Security Disability Insurance; SSI, Supplemental Security Income; US, United States.

^a Calculated by dividing the total number of beneficiaries excluding beneficiaries with schizophrenia by the total US population in 2019.

^b Calculated by multiplying the total number of beneficiaries with schizophrenia or other psychotic disorder by 43.7%⁹⁶, the share of schizophrenia as a proportion of other psychotic diseases.

^c Calculated by dividing the estimated number of beneficiaries with schizophrenia by the total schizophrenia population in 2019.

^d Ratio of the annualized probability of violent victimization in people with schizophrenia and the probability of violent victimization in the general US population.

Remission versus relapse

Table 11 depicts the inputs utilized to distinguish between individuals with symptoms of schizophrenia relapse versus remission.

Table 11 – Likelihood of social state transitions and fiscal consequences in people in remission and relapse

Description	Remission	Relapse	SE	Source
Social states				
Homeless/sheltered (rate ratio) ^a	0.30	1.47	[0.47], [0.22]	108
Arrests	0.70	2.36	[0.24], [0.28]	101
Fiscal consequences				
Any employment (rate ratio) ^a	1.66	0.55	[0.07], [0.10]	108
Has a caregiver (rate ratio)	0.42	1.40	[0.16], [0.13]	
Weekly hours of informal care	26.03	39.26	[3.64], [4.50]	
Victimization	0.87	1.33	[0.16], [0.24]	101

Acronyms: SE, standard error

^a Rate ratios compare the likelihood of an event in people with schizophrenia in remission or relapse versus the general population of people with schizophrenia.

4. Fiscal costs and economic consequences

Membership to different social states determined the likelihood of economic consequences, as explained in the section above. The economic value of these consequences was sourced from peer reviewed or nationally US data and inflated to 2021 US dollars using the Consumer Price Index.¹²⁷ Table 12 summarizes the main inputs informing the monetary value of fiscal consequences and respective sources. Measures of variance for cost data were frequently not reported. We have therefore assumed that standard errors for these inputs would be 20% of the mean. This allowed estimating confidence intervals to be used in one-way sensitivity analysis.

Table 12 – Monetary value of fiscal and economic consequences

Description	Input ^a		Source
Average gross income from employment			
Age groups	Males	Females	128
75+ Years	\$51,844	\$31,950	
65 to 74 years	\$67,958	\$41,096	
55 to 64 years	\$86,013	\$51,779	
45 to 54 years	\$91,329	\$60,186	
35 to 44 years	\$83,334	\$56,341	
25 to 34 years	\$57,014	\$44,767	
15 to 24 years	\$21,859	\$19,971	
Direct and indirect tax inputs			
Tax Wedge US	28.4%		115
Disposable income	51.5%		117
Average tax in the US	10.1%		116
Disability transfers			
Monthly SSDI	All beneficiaries	With schizophrenia ^b	
65+	\$1,389	\$1,089	119

60–64	\$1,410	\$1,105	
55–59	\$1,311	\$1,027	
50–54	\$1,233	\$966	
45–49	\$1,161	\$909	
40–44	\$1,076	\$843	
35–39	\$989	\$775	
30–34	\$895	\$702	
25–29	\$813	\$637	
Under 25	\$751	\$589	
Average monthly benefit, by sex and diagnostic group (USD 2019)			
Total (all disabled beneficiaries)	\$1,258		119
People with schizophrenia and other psychotic disorders	\$986		
Weight benefits in people with schizophrenia vs other disabilities	78.4% ^c		Calculated
Average SSI income (monthly)	\$748		119
Criminal justice and incarceration			
Costs per arrest	\$2,910		129
Daily costs of incarceration - State and federal prisons	\$269		130
Daily costs of incarceration - Jails	\$161		
Direct medical costs			
Total personal healthcare per capita in the general US population			
85+	\$37,083		131
65-84	\$19,134		
45-64	\$11,509		
19-44	\$5,473		
0-18	\$4,225		
19 to 24 years	\$23,518		
Annual healthcare costs for incarcerated individuals without schizophrenia	\$7,113		132
Annual healthcare costs for people with schizophrenia with justice involvement	\$31,862		133
Annual healthcare costs in people with schizophrenia without justice involvement	\$43,876		
Annual healthcare costs if homeless	\$11,520		134
Victimization			
Violent victimization - Police costs per crime	\$6,081		130
Homelessness			
Homelessness costs (excluding healthcare)	\$50,669		134

Acronyms: SE, standard error; SSDI, Social Security Disability Insurance; SSI, Supplemental Security Income; USD, United States dollars.

^a Costs are shown in 2021 US dollars. When required, costs were inflated using the US consumer price index.¹²⁷

^b Estimated from the values for all disabled beneficiaries using a calculated ratio between the average amounts received by all beneficiaries and the cohort with schizophrenia and other psychotic disorders (78.4%).

^c Ratio of average monthly benefit for people with schizophrenia and other psychotic disorders and all disabled beneficiaries.

5. Additional results

Figure 1 – Social state occupancy, model trace – General population





Figure 2 – Social state occupancy, model trace – Cohort affected by schizophrenia



6. References

1. Minter M. Physician Survey Indicates Need for Novel Antipsychotics: William Blair, 2021.
2. Bareis N, Olfson M, Wall M, et al. Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. *Psychiatric Services* 2021;73(5):492-500. doi: 10.1176/appi.ps.202000932
3. Fuller DA. RESEARCH WEEKLY: 2016 Prevalence of Treated and Untreated Severe Mental Illness by State: Treatment Advocacy Centre,; 2017 [accessed 03/04/2023].
4. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. *Biol Psychiatry* 1997;42(4):233-46. doi: 10.1016/s0006-3223(97)00190-x [published Online First: 1997/08/15]
5. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. *J Clin Psychopharmacol* 1996;16(2):158-69. doi: 10.1097/00004714-199604000-00008 [published Online First: 1996/04/01]
6. Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. *Am J Psychiatry* 2009;166(6):691-701. doi: 10.1176/appi.ajp.2009.08040613 [published Online First: 2009/05/05]
7. Cutler AJ, Tran-Johnson T, Kalali A, et al. A failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. *Psychopharmacol Bull* 2010;43(4):37-69. [published Online First: 2011/01/18]
8. Hatta K, Sato K, Hamakawa H, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. *Schizophr Res* 2009;113(1):49-55. doi: 10.1016/j.schres.2009.05.030 [published Online First: 2009/06/26]
9. Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2007;68(6):832-42. doi: 10.4088/jcp.v68n0603 [published Online First: 2007/06/27]
10. Lindenmayer JP, Brown D, Liu S, et al. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. *Psychopharmacol Bull* 2008;41(3):11-35. [published Online First: 2008/09/10]
11. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. *Schizophr Res* 2013;145(1-3):101-9. doi: 10.1016/j.schres.2013.01.009 [published Online First: 2013/02/19]
12. Marder SR, Hakala M, Gislum M, et al. An interventional, multi-center, randomized, double-blind, placebo-controlled, active reference, flexible dose study of brexpiprazole in adults with acute schizophrenia. *European Psychiatry* 2016;33:S99. doi: <https://doi.org/10.1016/j.eurpsy.2016.01.075>
13. Sacchetti E, Valsecchi P, Parrinello G. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. *Schizophr Res* 2008;98(1-3):55-65. doi: 10.1016/j.schres.2007.09.011 [published Online First: 2007/10/16]
14. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. *Arch Gen Psychiatry* 1997;54(6):549-57. doi: 10.1001/archpsyc.1997.01830180067009 [published Online First: 1997/06/01]
15. Zhong KX, Sweitzer DE, Hamer RM, et al. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. *J Clin Psychiatry* 2006;67(7):1093-103. doi: 10.4088/jcp.v67n0712 [published Online First: 2006/08/08]
16. Li Y, Li H, Liu Y, et al. Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study. *Current Medical Research and Opinion* 2012;28(10):1725-32. doi: 10.1185/03007995.2012.728524
17. Riedel M, Müller N, Spellmann I, et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2007;257(7):402-12. doi: 10.1007/s00406-007-0748-9 [published Online First: 2007/07/17]
18. Cantillon M, Prakash A, Alexander A, et al. Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. *Schizophr Res* 2017;189:126-33. doi: 10.1016/j.schres.2017.01.043 [published Online First: 2017/02/22]
19. Chan HY, Lin WW, Lin SK, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. *J Clin Psychiatry* 2007;68(1):29-36. doi: 10.4088/jcp.v68n0104 [published Online First: 2007/02/08]

20. Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. *Int Clin Psychopharmacol* 2016;31(4):192-201. doi: 10.1097/yic.000000000000123 [published Online First: 2016/03/11]
21. Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. *Biol Psychiatry* 2009;65(6):510-7. doi: 10.1016/j.biopsych.2008.07.033 [published Online First: 2008/11/07]
22. Jindal KC, Singh GP, Munjal V. Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India. *Int J Psychiatry Clin Pract* 2013;17(1):21-9. doi: 10.3109/13651501.2011.653376 [published Online First: 2012/02/22]
23. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. *J Clin Psychiatry* 2002;63(9):763-71. doi: 10.4088/jcp.v63n0903 [published Online First: 2002/10/05]
24. Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. *J Clin Psychiatry* 2009;70(4):572-81. doi: 10.4088/jcp.08m04421 [published Online First: 2009/03/28]
25. Li H, Luo J, Wang C, et al. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. *Schizophr Res* 2014;157(1-3):112-9. doi: 10.1016/j.schres.2014.05.040 [published Online First: 2014/07/06]
26. McEvoy JP, Daniel DG, Carson WH, Jr., et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. *J Psychiatr Res* 2007;41(11):895-905. doi: 10.1016/j.jpsychires.2007.05.002 [published Online First: 2007/07/17]
27. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. *Arch Gen Psychiatry* 2003;60(7):681-90. doi: 10.1001/archpsyc.60.7.681 [published Online First: 2003/07/16]
28. Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. *Int Clin Psychopharmacol* 2007;22(6):363-70. doi: 10.1097/YIC.0b013e32816f7779 [published Online First: 2007/10/06]
29. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. *Schizophrenia Research* 2014;152(2):450-57. doi: <https://doi.org/10.1016/j.schres.2013.11.041>
30. Litman RE, Smith MA, Doherty JJ, et al. AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. *Schizophr Res* 2016;172(1-3):152-7. doi: 10.1016/j.schres.2016.02.001 [published Online First: 2016/02/29]
31. Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. *J Clin Psychiatry* 2004;65(12):1624-33. doi: 10.4088/jcp.v65n1207 [published Online First: 2005/01/12]
32. Chen JJ, Chan HY, Chen CH, et al. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. *Pharmacopsychiatry* 2012;45(2):64-71. doi: 10.1055/s-0031-1291293 [published Online First: 2011/11/17]
33. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. *J Clin Psychopharmacol* 1993;13(1):25-40. [published Online First: 1993/02/01]
34. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2001;158(5):765-74. doi: 10.1176/appi.ajp.158.5.765 [published Online First: 2001/05/01]
35. Downing AM, Kinon BJ, Millen BA, et al. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia. *BMC Psychiatry* 2014;14:351. doi: 10.1186/s12888-014-0351-3 [published Online First: 2014/12/30]
36. Feng Y, Shi J, Wang L, et al. Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. *Psychiatry Clin Neurosci* 2020;74(6):336-43. doi: 10.1111/pcn.12965 [published Online First: 2019/12/12]
37. Ghaleiha A, Honarbakhsh N, Boroumand MA, et al. Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. *Hum Psychopharmacol* 2011;26(2):120-4. doi: 10.1002/hup.1176 [published Online First: 2011/03/18]

38. Heinrich K, Klieser E, Lehmann E, et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. *Prog Neuropsychopharmacol Biol Psychiatry* 1994;18(1):129-37. doi: 10.1016/0278-5846(94)90029-9 [published Online First: 1994/01/01]
39. Higuchi T, Iyo M, Kwon JS, et al. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial. *Asia Pac Psychiatry* 2019;11(3):e12354. doi: 10.1111/appy.12354 [published Online First: 2019/03/27]
40. Hwang TJ, Lee SM, Sun HJ, et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. *J Formos Med Assoc* 2003;102(1):30-6. [published Online First: 2003/04/10]
41. Peuskens J, Bech P, Möller HJ, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. *Psychiatry Res* 1999;88(2):107-17. doi: 10.1016/s0165-1781(99)00075-x [published Online First: 2000/01/06]
42. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. *J Clin Psychiatry* 2007;68(10):1492-500. doi: 10.4088/jcp.v68n1004 [published Online First: 2007/10/27]
43. Zhang H, Li H, Shu L, et al. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. *Neuropsychiatr Dis Treat* 2011;7:77-85. doi: 10.2147/ndt.S16664 [published Online First: 2011/05/10]
44. Potkin SG, Litman RE, Torres R, et al. Efficacy of loperidone in the Treatment of Schizophrenia: Initial Phase 3 Studies. *Journal of Clinical Psychopharmacology* 2008;28(2)
45. Geffen Y, Keefe R, Rabinowitz J, et al. BI-1020, a new γ -aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. *J Clin Psychiatry* 2012;73(9):e1168-74. doi: 10.4088/JCP.12m07642 [published Online First: 2012/10/13]
46. Casey DE, Sands EE, Heisterberg J, et al. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. *Psychopharmacology (Berl)* 2008;200(3):317-31. doi: 10.1007/s00213-008-1207-7 [published Online First: 2008/07/04]
47. Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. *Biol Psychiatry* 2016;79(12):952-61. doi: 10.1016/j.biopsych.2015.08.026 [published Online First: 2015/10/08]
48. Beasley CM, Jr., Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. *Neuropsychopharmacology* 1996;14(2):111-23. doi: 10.1016/0893-133x(95)00069-p [published Online First: 1996/02/01]
49. Bugarski-Kirola D, Wang A, Abi-Saab D, et al. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study. *Eur Neuropsychopharmacol* 2014;24(7):1024-36. doi: 10.1016/j.euroneuro.2014.03.007 [published Online First: 2014/04/17]
50. Corrigan MH, Gallen CC, Bonura ML, et al. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. *Biol Psychiatry* 2004;55(5):445-51. doi: 10.1016/j.biopsych.2003.10.004 [published Online First: 2004/03/17]
51. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. *Schizophr Res* 2007;93(1-3):117-30. doi: 10.1016/j.schres.2007.03.003 [published Online First: 2007/05/01]
52. Egan MF, Zhao X, Smith A, et al. Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia. *Hum Psychopharmacol* 2013;28(2):124-33. doi: 10.1002/hup.2289 [published Online First: 2013/03/28]
53. Grootens KP, van Veelen NM, Peuskens J, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. *Schizophr Bull* 2011;37(2):352-61. doi: 10.1093/schbul/sbp037 [published Online First: 2009/06/23]
54. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. *Schizophr Res* 2007;90(1-3):147-61. doi: 10.1016/j.schres.2006.09.012 [published Online First: 2006/11/10]
55. Kinon BJ, Zhang L, Millen BA, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. *J Clin Psychopharmacol* 2011;31(3):349-55. doi: 10.1097/JCP.0b013e318218dcd5 [published Online First: 2011/04/22]
56. Landbloom R, Mackle M, Wu X, et al. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as

- an active control. *CNS Spectr* 2017;22(4):333-41. doi: 10.1017/s1092852916000377 [published Online First: 2016/11/09]
57. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. *Biol Psychiatry* 2007;62(12):1363-70. doi: 10.1016/j.biopsych.2007.01.017 [published Online First: 2007/07/03]
 58. Martin S, Ljo H, Peuskens J, et al. A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. *Curr Med Res Opin* 2002;18(6):355-62. doi: 10.1185/030079902125001128 [published Online First: 2002/11/22]
 59. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. *Am J Psychiatry* 2011;168(9):957-67. doi: 10.1176/appi.ajp.2011.10060907 [published Online First: 2011/06/17]
 60. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. *Nat Med* 2007;13(9):1102-7. doi: 10.1038/nm1632 [published Online First: 2007/09/04]
 61. Pawar GR, Phadnis P, Paliwal A. Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial. *ISRN Psychiatry* 2012;2012:703751. doi: 10.5402/2012/703751 [published Online First: 2012/01/01]
 62. Potkin SG, Kunovac J, Silverman BL, et al. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study. *J Clin Psychiatry* 2020;81(2) doi: 10.4088/JCP.19m12769 [published Online First: 2020/03/07]
 63. Schmidt ME, Kent JM, Daly E, et al. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia. *Eur Neuropsychopharmacol* 2012;22(10):721-33. doi: 10.1016/j.euroneuro.2012.02.007 [published Online First: 2012/04/03]
 64. Shah S, Joshi D. Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: A randomized, double-blind, multicentric trial. *Ind Psychiatry J* 2011;20(1):25-31. doi: 10.4103/0972-6748.98411 [published Online First: 2011/01/01]
 65. Shen JH, Zhao Y, Rosenzweig-Lipson S, et al. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. *J Psychiatr Res* 2014;53:14-22. doi: 10.1016/j.jpsychires.2014.02.012 [published Online First: 2014/03/13]
 66. Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2004;161(10):1837-47. doi: 10.1176/ajp.161.10.1837 [published Online First: 2004/10/07]
 67. Schoemaker J, Naber D, Vrijland P, et al. Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder. *Pharmacopsychiatry* 2011;44(7):343. doi: 10.1055/s-0031-1295450 [published Online First: 2011/11/19]
 68. Higuchi T, Ishigooka J, Iyo M, et al. Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients. *Asia Pac Psychiatry* 2019;11(2):e12352. doi: 10.1111/appy.12352 [published Online First: 2019/04/06]
 69. Loebel A, Silva R, Goldman R, et al. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. *J Clin Psychiatry* 2016;77(12):1672-80. doi: 10.4088/JCP.16m10698 [published Online First: 2016/07/28]
 70. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. *J Clin Psychiatry* 2009;70(6):829-36. doi: 10.4088/JCP.08m04905 [published Online First: 2009/06/06]
 71. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. *J Psychiatr Res* 2013;47(5):670-7. doi: 10.1016/j.jpsychires.2013.01.020 [published Online First: 2013/02/21]
 72. Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. *Psychopharmacology (Berl)* 2013;225(3):519-30. doi: 10.1007/s00213-012-2838-2 [published Online First: 2012/08/21]
 73. Potkin SG, Kimura T, Guarino J. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. *Ther Adv Psychopharmacol* 2015;5(6):322-31. doi: 10.1177/2045125315606027 [published Online First: 2016/02/03]

74. O'Day K, Rajagopalan K, Meyer K, et al. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. *Clinicoecon Outcomes Res* 2013;5:459-70. doi: 10.2147/CEOR.S47990
75. Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. *The Lancet* 2022;399(10327):824-36. doi: 10.1016/s0140-6736(21)01997-8
76. Kotov R, Fochtmann L, Li K, et al. Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project. *Am J Psychiatry* 2017;174(11):1064-74. doi: 10.1176/appi.ajp.2017.16101191 [published Online First: 2017/08/05]
77. Gidwani R, Russell LB. Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers. *Pharmacoeconomics* 2020;38(11):1153-64. doi: 10.1007/s40273-020-00937-z [published Online First: 2020/08/17]
78. Pilon D, Tandon N, Lafeuille M-H, et al. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. *Clinical Therapeutics* 2017;39(10):1972-85.e2. doi: 10.1016/j.clinthera.2017.08.008
79. Arias E, Xu J. United States Life Tables, 2018: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES; 2020 [Available from: <https://www.cdc.gov/nchs/data/nvsr/nvsr69/nvsr69-12-508.pdf> accessed 30/03/2021 2021.
80. Heron M. Deaths: Leading cause for 2018: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES; 2021 [Available from: <https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-04-508.pdf> accessed 30/07/2021 2021.
81. Olfson M, Stroup TS, Huang C, et al. Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span. *JAMA Psychiatry* 2021;78(8):876-85. doi: 10.1001/jamapsychiatry.2021.0841 [published Online First: 2021/05/27]
82. Framingham Heart Study team. FHS Cardiovascular Disease (10-year risk) 2022 [10/02/2022]. Available from: <https://framinghamheartstudy.org/fhs-risk-functions/cardiovascular-disease-10-year-risk/> accessed 10/02/2022.
83. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation* 2008;117(6):743-53. doi: 10.1161/circulationaha.107.699579 [published Online First: 2008/01/24]
84. O'Sullivan AK, Rubin J, Nyambose J, et al. Cost Estimation of Cardiovascular Disease Events in the US. *PharmacoEconomics* 2011;29(8):693-704. doi: 10.2165/11584620-000000000-00000
85. Fryar CD, Carroll MD, Gu Q, et al. Anthropometric Reference Data for Children and Adults: United States, 2015–2018: National Center for Health Statistics; 2021 [3 (46):[Available from: file:///C:/Users/ruima/Downloads/CDC%20-%20weight%20height.pdf.
86. Wright JD, Hughes JP, Ostchega Y, et al. Mean Systolic and Diastolic Blood Pressure in Adults Aged 18 and Over in the United States, 2001–2008 2011 [Available from: <https://www.cdc.gov/nchs/data/nhsr/nhsr035.pdf> accessed 17/11/2021.
87. CDC. National Diabetes Statistics Report, 2020 Atlanta, GA: : Centers for Disease Control and Prevention; 2020 [Available from: <https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf> accessed 17/11/2021.
88. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. *World J Diabetes* 2017;8(8):390-96. doi: 10.4239/wjd.v8.i8.390
89. Cornelius ME, Wang TW, Jamal A, et al. Tobacco Product Use Among Adults — United States, 2019 United States 2020 [69:[Available from: <https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6946a4-H.pdf> accessed 17/11/2021.
90. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. *Schizophr Res* 2005;76(2-3):135-57. doi: 10.1016/j.schres.2005.02.010 [published Online First: 2005/06/14]
91. Bonczar. Prevalence of Imprisonment in the US population 1974-2001 2003 [Available from: <https://www.bjs.gov/content/pub/pdf/piusp01.pdf> accessed 31.03.2021.
92. Bonczar TP, Beck AJ. Lifetime Likelihood of Going to State or Federal Prison 1997 [Available from: <https://www.bjs.gov/index.cfm?ty=pbdetail&iid=1042>.
93. Maruschak L.M., Minton T.D. Correctional Populations in the United States, 2017-2018 2020 [Available from: <https://www.bjs.gov/index.cfm?ty=pbdetail&iid=7026> accessed 16/04/2021.
94. Prins SJ. Prevalence of mental illnesses in US State prisons: a systematic review. *Psychiatric services (Washington, DC)* 2014;65(7):862-72. doi: 10.1176/appi.ps.201300166
95. Bronson J, Berzofsky M. Indicators of Mental Health Problems Reported by Prisoners and Jail Inmates, 2011-12 2017 [Available from: <https://www.bjs.gov/content/pub/pdf/imhprpji1112.pdf> accessed 15/04/2021.
96. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. *Arch Gen Psychiatry* 2007;64(1):19-28. doi: 10.1001/archpsyc.64.1.19 [published Online First: 2007/01/03]

97. James DJ, Glaze LE. Mental Health Problems of Prison and Jail Inmates: U.S. Department of Justice; 2006 [Available from: <https://bjs.ojp.gov/content/pub/pdf/mhppji.pdf> accessed 25/08/2021.
98. Kaeble D. Time Served in State Prison, 2018: US Department of Justice; 2021 [Available from: <https://www.ojp.gov/library/publications/time-served-state-prison-2018> accessed 08/09/2021.
99. Durose MR, Antenangeli L. Recidivism of Prisoners Released in 34 States in 2012: A 5-Year Follow-Up Period (2012–2017). *US Department of Justice* 2021
100. Greenberg GA, Rosenheck RA. Jail Incarceration, Homelessness, and Mental Health: A National Study. *Psychiatric Services* 2008;59(2):170-77. doi: 10.1176/ps.2008.59.2.170
101. Haynes VS, Zhu B, Stauffer VL, et al. Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. *BMC Psychiatry* 2012;12:222. doi: 10.1186/1471-244x-12-222 [published Online First: 2012/12/12]
102. US Census Bureau. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2020 to July 1, 2021 2022 [Available from: <https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html> accessed 13/09/2022.
103. SAMHSA. Current Statistics on the Prevalence and Characteristics of People Experiencing Homelessness in the United States 2011 [Available from: https://www.homelesshub.ca/sites/default/files/attachments/hrc_factsheet.pdf.
104. US Census Bureau. Intercensal Estimates of the Resident Population by Sex and Age for the United States: April 1, 2000 to July 1, 2010 (Table 1) 2011 [Available from: <https://www.census.gov/data/tables/time-series/demo/popest/intercensal-2000-2010-national.html> accessed 19/04/2021.
105. Ayano G, Tesfaw G, Shumet S. The prevalence of schizophrenia and other psychotic disorders among homeless people: a systematic review and meta-analysis. *BMC Psychiatry* 2019;19(1):370. doi: 10.1186/s12888-019-2361-7 [published Online First: 2019/11/30]
106. U.S. Department of Housing and Urban Development. The 2020 Annual Homeless Assessment Report (AHAR) to Congress 2020 [Available from: <https://www.huduser.gov/portal/sites/default/files/pdf/2020-AHAR-Part-1.pdf>.
107. Remster B. A Life Course Analysis of Homeless Shelter Use among the Formerly Incarcerated. *Justice Quarterly* 2019;36(3):437-65. doi: 10.1080/07418825.2017.1401653
108. Martins R, Kadakia A, Fan A, et al. Assessing the risk of health, social and fiscal events in schizophrenia according to remission or relapse status using real world data from a US survey. Neuroscience Education Institute (NEI) Congress. Colorado Springs, Colorado, 2021.
109. Metraux S, Culhane DP. Homeless shelter use and reincarceration following prison release. *Criminology & Public Policy* 2004;3(2):139-60. doi: <https://doi.org/10.1111/j.1745-9133.2004.tb00031.x>
110. US Bureau of Labor Statistics. Employment status of the civilian noninstitutional population by age, sex, and race 2021 [Available from: <https://www.bls.gov/cps/cpsaat03.htm> accessed 14/09/2021.
111. Zwerling C, Whitten PS, Sprince NL, et al. Workforce participation by persons with disabilities: the National Health Interview Survey Disability Supplement, 1994 to 1995. *J Occup Environ Med* 2002;44(4):358-64. doi: 10.1097/00043764-200204000-00017 [published Online First: 2002/04/30]
112. Csoboth C, Witt EA, Villa KF, et al. The humanistic and economic burden of providing care for a patient with schizophrenia. *Int J Soc Psychiatry* 2015;61(8):754-61. doi: 10.1177/0020764015577844 [published Online First: 2015/04/01]
113. Lilly MB, Laporte A, Coyte PC. Do they care too much to work? The influence of caregiving intensity on the labour force participation of unpaid caregivers in Canada. *J Health Econ* 2010;29(6):895-903. doi: 10.1016/j.jhealeco.2010.08.007 [published Online First: 2010/09/25]
114. National Alliance for Caregiving. Caregiving in the U.S.: National Alliance for Caregiving; 2020 [Available from: <https://www.aarp.org/content/dam/aarp/ppi/2020/05/full-report-caregiving-in-the-united-states.doi.10.26419-2Fppi.00103.001.pdf> accessed 28/09/2021.
115. OECD OfEC-oad. Taxing Wages - The United States 2021 [Available from: <https://www.oecd.org/unitedstates/taxing-wages-united-states.pdf> accessed 01/09/2021.
116. IRS. All Individual Returns Excluding Dependents, Tax Years 2001-2018 2021 [Available from: <https://www.irs.gov/pub/irs-soi/18in02etr.xls> accessed 15/09/2021.
117. OECD. Social Protection and Well-being: Income distribution database by country 2021 [Available from: <https://stats.oecd.org/Index.aspx?DataSetCode=IDD> accessed 15/09/2021.
118. Reaves BA. Felony Defendants in Large Urban Counties, 2009 - Statistical Tables: Bureau of Justice Statistics; 2013 [Available from: <https://bjs.ojp.gov/content/pub/pdf/fdluc09.pdf> accessed 27/09/2021.
119. SSA. Annual Statistical Report on the Social Security Disability Insurance Program 2019 [Available from: https://www.ssa.gov/policy/docs/statcomps/di_asr/2019/index.html accessed 24-09-2021.
120. Social Security Administration. Annual Statistical Report on the Social Security Disability Insurance Program, 2019 2020 [Available from: https://www.ssa.gov/policy/docs/statcomps/di_asr/index.html accessed 06/05/2021.

121. Morgan RE, Truman JL. Criminal Victimization, 2019 2020 [accessed 04/10/2021].
122. Brekke JS, Prindle C, Bae SW, et al. Risks for Individuals With Schizophrenia Who Are Living in the Community. *Psychiatric Services* 2001;52(10):1358-66. doi: 10.1176/appi.ps.52.10.1358
123. US Census Bureau. Health Insurance Coverage Status and Type of Coverage - All Persons by Age and Sex: 2017 to 2020 2021 [Available from: <https://www.census.gov/library/publications/2021/demo/p60-274.html> accessed 28/02/2022].
124. Kadakia A, Fan Q, Shepherd J, et al. Real-world outcomes for schizophrenia patients and caregivers by disease severity. In: Inc. SbSP, Poster presented at the Schizophrenia International Research Society (SIRS) Congress 2021, April 17–21, Virtual Conference, eds., 2021.
125. Khaykin E, Eaton WW, Ford DE, et al. Health insurance coverage among persons with schizophrenia in the United States. *Psychiatr Serv* 2010;61(8):830-4. doi: 10.1176/ps.2010.61.8.830 [published Online First: 2010/08/03]
126. US Census Bureau. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2010 to July 1, 2019 2020 [Available from: <https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-detail.html> accessed 19/04/2021].
127. US Bureau of Economic Analysis. Price Indexes for Personal Consumption Expenditures by Major Type of Product [Table 2.3.4.] 2022 [Available from: <https://apps.bea.gov/iTable/iTable.cfm?reqid=19&step=2#reqid=19&step=2&isuri=1&1921=survey> accessed 14/09/2022].
128. US Census Bureau. Historical income tables people by mean income and sex (2019) (Table 9) 2021 [Available from: <https://www.census.gov/data/tables/time-series/demo/income-poverty/historical-income-people.html> accessed 06/05/2021].
129. Swanson JW, Frisman LK, Robertson AG, et al. Costs of criminal justice involvement among persons with serious mental illness in connecticut. *Psychiatr Serv* 2013;64(7):630-7. doi: 10.1176/appi.ps.002212012 [published Online First: 2013/03/16]
130. Cloutier M, Aigbogun MS, Guerin A, et al. The Economic Burden of Schizophrenia in the United States in 2013. *J Clin Psychiatry* 2016;77(6):764-71. doi: 10.4088/JCP.15m10278 [published Online First: 2016/05/03]
131. CMS. Total Personal Health Care Per-capita Spending by Gender and Age Group, 2014 (Table 7) 2021 [Available from: <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Age-and-Gender> accessed 23/01/2022].
132. Huh K, Boucher A, McGaffey F, et al. Prison Health Care Costs Quality. Philadelphia, PA: Pew Charitable Trusts 2017 [Available from: <https://www.pewtrusts.org/en/research-and-analysis/reports/2017/10/prison-health-care-costs-and-quality> accessed 24/02/2022].
133. Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia. *BMC Psychiatry* 2010;10(1):11. doi: 10.1186/1471-244X-10-11
134. Spellman B, Khadduri J, Sokol B, et al. Costs associated with first-time homelessness for families and individuals: US Department of Housing and Urban Development; 2010 [Available from: https://www.huduser.gov/publications/pdf/costs_homeless.pdf].